Historical dgx News Stories
Quest Diagnostics Q4 Beat AI Companion Fuels Rally
Quest Diagnostics (DGX) posted a strong Q4, raised 2026 guidance, expanded shareholder returns and launched the Quest AI Companion—moves that underpinned a double-digit stock rally and signal a tighter focus on consumer engagement and strategic growth.
DGX Upside: AI Tool Launch and Medicare Relief
Recent concrete developments for Quest Diagnostics (DGX) — the launch of a Gemini-powered Quest AI Companion, a one-year delay to PAMA/CLFS Medicare cuts, and clarified CMS reporting guidance — together provide short-term revenue protection and a digital differentiation that could support DGX's operational resilience and investor outlook.
Quest Diagnostics: Corewell JV Boosts DGX Value Q1
Quest Diagnostics finalized a 51/49 joint venture with Corewell Health to operate Diagnostic Lab of Michigan, rolling out Collaborative Lab Solutions across 21 hospitals and planning a 100,000 sq ft lab for Q1 2027. The transaction strengthens DGX’s regional scale and recurring revenue potential while underscoring the need to monitor reimbursement pressures and execution of productivity initiatives.
Quest Diagnostics Clears LDT Risk — Stock Up Today
Quest Diagnostics (DGX) received a near-term regulatory relief after a court vacated the FDA's proposed oversight of laboratory-developed tests (LDTs) and the agency declined to appeal. Coupled with a recent earnings beat, raised guidance, a dividend increase and a $1B buyback, DGX shares have climbed sharply. Parallel industry trends—especially AI-driven claims automation—offer structural tailwinds that could improve reimbursement efficiency for diagnostic labs.
Quest Diagnostics Surges: MRD Test, Dividend Boost
Quest Diagnostics (DGX) posted strong Q4 results, introduced a blood-based MRD test for multiple myeloma, and announced a meaningful dividend increase plus a $1 billion buyback authorization. These concrete developments strengthen DGX’s growth and shareholder-return thesis, while Medicare reimbursement pressure and ongoing IT modernization remain key operational factors to monitor.
DGX: Beat, Dividend Hike, Medicare Cut Risk Ahead.
Quest Diagnostics (DGX) reported a Q4 beat, raised 2026 guidance, boosted its dividend and expanded buybacks—sparking a notable share gain—while looming Medicare reimbursement cuts for hundreds of lab tests create a tangible near-term policy risk.
Quest Diagnostics Jumps After Q4 Beat, Big Buyback
Quest Diagnostics (DGX) surged after reporting a stronger-than-expected Q4 with revenue of $2.81B and adjusted EPS of $2.42, while announcing a 7.5% dividend increase and $1B additional share buyback authorization. Analysts raised price targets and the stock briefly hit a 52-week high, signaling investor confidence tied to durable diagnostic demand and robust capital returns.
DGX Ahead of Earnings: Corewell JV Boosts Outlook!
Quest Diagnostics (DGX) rallied last week as investors weighed an upcoming Q4 & full-year 2025 earnings release and the completed Corewell Health joint venture. Recent price gains, volume upticks, and corporate recognition position DGX ahead of its Feb. 10, 2026 results; near-term direction will hinge on revenue trends, diagnostic volumes, and guidance.